Abstract
Background Little is known about the population prevalence of antibodies against emerging immune escape variants of SARS-CoV-2.
Methods A population-based prevalence study was conducted in Yokohama City, the most populous municipality of Japan. Quantitative measurements of immunoglobulin G against SARS-CoV-2 spike protein (SP-IgG) and qualitative measurements of neutralization antibodies against the Omicron BA.1 and BA.2 variants were performed.
Results Of 6,000 randomly selected residents aged 20–74, 1,277 participated in the study during a period from January 30 to February 28, 2022. Of them, 3% had prior diagnosis of COVID-19, 96% received at least two-doses of SARS-CoV-2 vaccines, and 94% were positive for SP-IgG. The positive rates of neutralizing antibodies were 28% to Omicron BA.1 and BA.2 variants in a random sample of 10% of participants (n=123) and 100% to BA.1 and BA.2 among participants who received the third vaccination at least 7 days before (n=66).
Conclusions In this population-based prevalence study in Japan, most had SP-IgG antibodies but the overall neutralizing antibody positive rate was 28% against the Omicron BA.1 and BA.2 variants. The population-level insufficient humoral immunity against the Omicron variants may explain the outbreak of COVID-19 during this period in Japan.
Competing Interest Statement
SY is an employee of Integrity Healthcare Co., Ltd. NO is an employee of Tosoh Corporation. These companies did not have any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. HK received grants from Shionogi & Company, Limited, and Asahi Kasei Pharma & Co., Inc. Other authors stated no conflict of interest.
Funding Statement
This work was supported by the grant for 2021-2022 Strategic Research Promotion (No.SK202116) of Yokohama City University. The work was also supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number: JP21fk0108104.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Yokohama City University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest SY is an employee of Integrity Healthcare Co., Ltd. NO is an employee of Tosoh Corporation. These companies did not have any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. HK received grants from Shionogi & Company, Limited, and Asahi Kasei Pharma & Co., Inc. Other authors stated no conflict of interest.
Funding Statement This work was supported by the grant for 2021–2022 Strategic Research Promotion (No.SK202116) of Yokohama City University. The work was also supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number: JP21fk0108104.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
